RT Journal Article
SR Electronic
T1 Systemic and Genetic Risk Factors for Reticular Macular Disease and Soft Drusen in Age-Related Macular Degeneration
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.27.21263712
DO 10.1101/2021.09.27.21263712
A1 Thomson, Robert J.
A1 Chazaro, Joshua
A1 Otero-Marquez, Oscar
A1 Ledesma-Gil, Gerardo
A1 Tong, Yuehong
A1 Coughlin, Arielle C.
A1 Teibel, Zachary R.
A1 Alauddin, Sharmina
A1 Tai, Katy
A1 Lloyd, Harriet
A1 Scolaro, Maria
A1 Govindaiah, Arun
A1 Bhuiyan, Alauddin
A1 Dhamoon, Mandip S.
A1 Deobhakta, Avnish
A1 Narula, Jagat
A1 Rosen, Richard B.
A1 Yannuzzi, Lawrence A.
A1 Freund, K. Bailey
A1 Smith, R. Theodore
YR 2021
UL http://medrxiv.org/content/early/2021/09/29/2021.09.27.21263712.abstract
AB Purpose Soft drusen and subretinal drusenoid deposits (SDD) aka reticular macular disease (RMD) characterize two pathways to advanced age-related macular degeneration (AMD). We propose these pathways are distinct diseases, with distinct genetic risks, serum risks and associated systemic diseases.Methods 126 Subjects with AMD had: retinal imaging for RMD status, serum risks, genetic testing, and histories of cardiovascular disease (CVD) and stroke.Results 62 subjects had RMD, 64 were nonRMD (drusen only), 51 had CVD or Stroke. RMD correlated significantly with: ARMS2 risk allele (p= 0.019); lower mean serum HDL (61±18 vs. 69±22 mg/dl, p= 0.038, t test); CVD and troke (34/51 RMD, p= 0.001).NonRMD correlated/trended with APOE2 (p= 0.032) and CETP (p= 0.072) risk alleles. 97 subjects total had some drusen, which correlated with CFH risk (p= 0.016). Multivariate independent risks for RMD were: CVD and Stroke (p= 0.008), and ARMS2 homozygous risk (p= 0.038).Conclusion The RMD and soft drusen AMD pathways have distinct systemic associations, serum and genetic risks. RMD is associated with CVD and stroke, ARMS2 risk, and lower HDL; drusen with CFH risk and two lipid risk genes. These pathways appear to be distinct diseases leading to advanced AMD.Summary Statement Two phenotypes of age-related macular degeneration, soft drusen and reticular macular disease (the combination of subretinal drusenoid deposits and choriocapillaris insufficiency), are shown here to have distinct systemic vascular, serum, and genetic risks. These findings support the concept that these phenotypes actually represent distinct disease processes.Competing Interest StatementRichard B. Rosen is a consultant to OptoVue, Boehringer-Ingelheim, Astellas, Genentech-Roche, NanoRetina, OD-OS, Regeneron, Bayer, Diopsys and Teva. He has personal financial interests in Opticology, Guardion and CellView. K. Bailey Freund is a consultant to Regeneron, Allergan, Zeiss, Bayer, Heidelberg Engineering and Novartis. He receives research funding from Genentech/Roche. R Theodore Smith is a consultant to Ora Technologies. The remaining authors have no relevant disclosures.Clinical TrialNCT04087356Funding StatementRegeneron Pharmaceuticals Investigator-Initiated Study, Research to Prevent Blindness Challenge Grant, Macula Foundation (KBF), Bayer-Global Ophthalmology Awards (GLG), International Council of Ophthalmology-Alcon Fellowship (OOM), New York Eye and Ear Infirmary Foundation (SA).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The institutional review board of Mount Sinai School of Medicine approved the study, which adhered to the tenets of the Declaration of Helsinki.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesn/a